
The U.S. FDA accepted Zydus Lifesciences Ltd. and Formycon AG’s BLA for FYB-206, a proposed biosimilar to Keytruda (pembrolizumab), putting the partners among the frontrunners pursuing a share of the $30 billion-plus oncology market commanded by Merck & Co. Inc.’s blockbuster drug.
Bioworld
Original source



